Pharmacologic effects in man of a potent, long-acting dopamine receptor agonist.
Single-dose administration of pergolide mesylate (100 to 400 micrograms) results in a dose-related inhibition of prolactin secretion which persists for more than 24 hours. During multiple-dose administration of pergolide, plasma prolactin concentrations remain markedly reduced (greater than 80 percnet) and gradually return to control levels several days after drug administration is discontinued.
D000328:Adult; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004873:Ergolines / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007258:Informed Consent; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011388:Prolactin / Q000097:blood; D011954:Receptors, Dopamine / Q000187:drug effects*; D013997:Time Factors
D004873:Ergolines; D010919:Placebos; D011954:Receptors, Dopamine; D011388:Prolactin